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Abstract:  We  present  a  label-free,  chemically-selective,  quantitative 
imaging  strategy  to  identify  breast  cancer  and  differentiate  its  subtypes 
using coherent anti-Stokes Raman scattering (CARS) microscopy. Human 
normal breast tissue, benign proliferative, as well as  in situ and invasive 
carcinomas, were imaged ex vivo. Simply by visualizing cellular and tissue 
features  appearing  on  CARS  images,  cancerous  lesions  can  be  readily 
separated  from  normal  tissue  and  benign  proliferative  lesion.  To  further 
distinguish cancer subtypes, quantitative disease-related features, describing 
the  geometry  and  distribution  of  cancer  cell  nuclei,  were  extracted  and 
applied to a computerized classification system. The results show that in situ 
carcinoma was successfully distinguished from invasive carcinoma, while 
invasive ductal carcinoma (IDC) and invasive lobular carcinoma were also 
distinguished from each other. Furthermore, 80% of intermediate-grade IDC 
and 85% of high-grade IDC were correctly distinguished from each other. 
The  proposed  quantitative  CARS  imaging  method  has  the  potential  to 
enable rapid diagnosis of breast cancer. 
© 2011 Optical Society of America 
OCIS codes: (170.3880) Medical and biological imaging; (170.4580) Optical diagnostics for 
medicine;  (180.4315)  Nonlinear  microscopy;  (300.6230)  Spectroscopy,  coherent  anti-Stokes 
Raman scattering microscopy 
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1. Introduction 
Breast cancer is the second leading cause of cancer-related deaths in women (1 in 8 women; 
about 13%) and accounts for approximately one-third of all cancers diagnosed among women 
in  the  United  States  [1].  The  American  Cancer  Society  estimated  230,480  new  cases  of 
invasive breast cancer and 57,650 new cases of in situ breast cancer, as well as approximately 
39,520 breast cancer-related deaths, in women in 2011 [2]. Therapeutic decisions are based on 
imaging  studies  and  pathologic  diagnosis,  neither  of  which  has  perfect  sensitivity  or 
specificity  [3,4].  As  the  gold  standard  for  clinical  diagnosis,  surgical  pathology  examines 
multiple histological features of tissues or cells (cell size, shape, and density or the formation 
of specific patterns) removed by surgeons or radiologists to characterize cancer lesions and 
their subtypes. The diagnostic process usually begins with a breast biopsy of either abnormal 
calcification or mass lesion, which is often performed by open surgery that removes the entire 
lesion, or by minimally-invasive core-needle biopsy that removes 5-12 cores of tissues to 
ensure  adequate  sampling.  The  excised  tissues  are  then  fixed,  sliced,  stained,  and  finally 
examined under a microscope by pathologists to make a diagnosis, resulting in a turnaround 
time  ranging  from  hours  to  days.  Frozen  sections  are  more  rapid,  but  are  usually  not 
performed on breast specimens because fatty tissue does not perform well in this technique. 
As a result of the long turnaround time for conventional histology, another procedure is often 
necessary because biopsies need to be repeated or margins need to be re-excised. Resulting 
delays or misdiagnosis in this process could directly lead to a missed opportunity to treat 
lesions early or unnecessarily aggressive therapies with harmful side-effects. Since diagnosis 
of cancer lesions plays a critical role in breast cancer prevention and treatments, a more rapid 
diagnostic  technique  could  potentially  reduce  the  number  of  repeated  procedures  while 
facilitating the whole process by allowing on-the-spot recognition of inadequate biopsies or 
positive margins. 
#148131 - $15.00 USD Received 24 May 2011; revised 24 Jun 2011; accepted 29 Jun 2011; published 5 Jul 2011
(C) 2011 OSA 1 August 2011 / Vol. 2, No. 8 / BIOMEDICAL OPTICS EXPRESS  2162In light of this, a variety of optical imaging techniques, such as fluorescence and Raman 
spectroscopies,  have  been  explored  to  improve  breast  cancer  diagnosis.  Fluorescence 
spectroscopy has been demonstrated as a useful tool in breast disease correlations through ex 
vivo  imaging  experiments  [5–7].  Although  fluorescence  imaging  provides  relatively  high 
signal-to-background ratio, the small number of endogenous fluorophores in breast tissue and 
their overlapping spectra limit its applications [8]. Raman spectroscopy is another modality 
that has been investigated for disease diagnosis. It functions to identify disease lesions by 
capturing  intrinsic  chemical  changes  within  tissues  [8].  Previous  study  has  successfully 
demonstrated  its  usefulness  in  identifying  carcinomas  by  having  a  sensitivity  of  94%,  a 
specificity of 96% and an overall accuracy of 86% [9]. However, this technique is limited by 
its long acquisition time (> 1 s/pixel) with high excitation power, preventing its applications 
from fast scanning of large surface areas with high spatial resolution [10]. Collectively, then, 
there is considerable interest in developing a fast, less invasive, and more objective method 
for the screening and diagnosis of breast cancer [11]. 
As  a  molecular  imaging  technique,  coherent  anti-Stokes  Raman  scattering  (CARS) 
microscopy  has  been  demonstrated  as  a  powerful  tool  for  label-free  imaging  with  sub-
wavelength  spatial  resolution  [12–15].  CARS  imaging  formulates  contrast  by  probing 
resonances  from  specific  chemical  bonds  in  unstained  samples,  enabling  its  chemical 
selectivity.  Its  coherent  nature  further  renders  CARS  signal  several  orders  of  magnitude 
stronger than the conventional Raman signal, thus offering video-rate imaging speed [16,17]. 
Therefore, this imaging modality has been successfully applied to a variety of biomedical 
applications, including the imaging of viruses, cells, tissues and live animals, as well as drug 
delivery  [12,18–25].  In  the  field  of  cancer  detection,  a  recent  study  showed  the  use  of 
multiplex  CARS  for  interferometric  imaging  of  breast  cancer  for  identification  of  cancer 
margins [26]. In this study,  breast tissues  were evaluated using their spectrum profile for 
construction of a digitized image for identification of tumor boundaries. The strategy was 
based on the chemically-selective modality of the CARS technique, but did not use its high 
spatial resolution in capturing cellular structures. 
Current pathology examination of stained breast biopsy samples focuses on changes in 
such cellular and histological features as cell size, cell-cell distance, and formation of fibrous 
structures [27]. Accurate identification of these features will lead to delineating the type of 
lesions for definitive treatment. However, conventional pathology examination is still subject 
to interobserver variations [4]. The CARS technique provides high-resolution images which 
can  clearly  detect  individual  cells  without  using  any  exogenous  agent  to  stain  tissue. 
Therefore, we hypothesized that a cell/tissue pattern recognition method could be developed 
using established pathological workup and diagnostic features as a basis for the quantitative 
classification  of  different  types  of  breast  lesions,  leading,  in  turn,  to  a  fast  examination 
strategy for the analysis of breast cancer samples. Accordingly, in this study, such disease-
related features as cell size, cell-cell distance and presence of fatty and fibrous structures were 
used for classification analysis. Cancerous lesions were initially separated from normal tissue 
and benign proliferative lesion using visual features such as the presence of fatty and fibrous 
structures. To further separate cancer subtypes, cellular features related to the morphology and 
distribution of cancer cell nucleus were extracted from ex vivo CARS images of human breast 
tissues,  including  ductal  carcinoma  in  situ  (DCIS),  invasive  ductal  carcinoma  (IDC),  and 
invasive  lobular  carcinoma  (ILC),  and  used  to  quantitatively  characterize  different  cancer 
subtypes through a classification strategy based on machine learning techniques. To the best 
of our knowledge, this pilot study demonstrates the first diagnostic platform with label-free 
and fast imaging properties with the potential to distinguish breast cancer from normal and 
benign  tissues  on  the  basis  of  quantitative  cellular  and  tissue  features  applied  to  a 
computerized classification system. 
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2.1. CARS microscopy 
As shown in Fig. 1, the schematic of our CARS microscopy consists of a laser source and a 
beam-scanning  microscope.  A  mode-locked  Nd:YVO4  laser  (High-Q  Laser,  Hohenems, 
Austria) provides a 7-ps pulse train at 1064 nm and a frequency-doubled, 5-ps pulse train at 
532 nm with repetition rate of 76 MHz. The 1064 nm pulse train is used as the Stokes wave 
for  CARS  process,  while  the  532  nm  pulse  train  is  used  to  pump  an  optical  parametric 
oscillator (OPO) (Levante Emerald, APE-Berlin, Germany). The OPO generates a 5-ps pulse 
train output, which has a tunable wavelength range of 680-980 nm and is used as the pump 
wave for CARS process. The pump and Stokes beams are overlapped by adjusting a time-
delay line in temporal domain and by the long-pass dichroic mirror DM1 (q1020lpxr, Chroma, 
VT) in spatial domain to satisfy the precondition for producing a CARS signal. The scanning 
microscope  is  modified  from  an  Olympus  FV300  confocal  microscope  adopting  a  2D 
galvanometer. A red-light-sensitive photomultiplier tube (R3896, Hamamatsu, Japan) is used 
as the detector, which can sensitively detect the major spectral range of our CARS emission. 
A 60X, 1.2-NA water-immersion microscope objective (IR UPlanApo, Olympus) was used 
for this study. The lateral and axial resolution is estimated to be approximately 0.4 µm and 0.9 
µm, respectively [28]. 
 
Fig. 1. Schematic of CARS microscopy. M: mirror, OPO: optical parametric oscillator, DL: 
delay line, DM: dichroic mirror, L: lens, MO: microscope objective, BT: breast tissue, BPF: 
band-pass filter, PMT: photomultiplier tube. 
2.2. Sample preparation 
Breast tissues were obtained from female patients undergoing surgical biopsy and surgery at 
The Methodist Hospital (TMH), Houston, TX, following Office of Human Subjects Research 
approval from The Methodist Hospital Research Institute (TMHRI). The excised tissues were 
immediately  snap-frozen  in  liquid  nitrogen  for  storage.  A  total  of  nineteen  patients  were 
enrolled in this study, including 4 cases of fibroadenoma, 2 cases of DCIS, 8 cases of IDC (2 
cases of intermediate-grade (IG-) IDC and 6 cases of high-grade (HG-) IDC), and 5 cases of 
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ILC. Frozen tissue samples were thawed at room temperature and then imaged ex vivo using 
the CARS microscope. Two to five sampling points were imaged for each specimen and a 
total of 48 sampling points were examined (9 from DCIS, 11 from IG-IDC, 17 from HG-IDC 
and 11 from ILC patients). At each sampling point, three images were acquired from different 
imaging  depths,  resulting  in  a  total  of  144  images  were  used  in  this  study.  After  CARS 
imaging, imaged places were marked with India blue, and samples were fixed in buffered 
formalin, sliced 5-μm thick, and finally stained with H&E, as a standard control of the disease 
type. 
2.3. Image acquisition 
Tissue samples were placed on a 170-μm cover slip and inverted on a rubber ring to form a 
sample chamber to avoid possible compression and associated morphologic changes of tissues 
during imaging [29]. The pump wavelength was tuned to 816.8 nm and the Stokes wavelength 
was fixed at 1,064 nm to reach a beating frequency of 2,845 cm
1, probing the symmetric CH2 
stretching band. The CARS signal at 663 nm was collected by the same objective, i.e., using a 
backward (Epi-) detection scheme. Then it was separated from the excitation waves by the 
long-pass dichroic  mirror DM2 (770dcxxr, Chroma, VT). Unwanted residual signals were 
blocked using a band-pass filter (BPF) (hq660/40m-2p, Chroma, VT). Image processing was 
performed using the Olympus Fluoview V5.0 software. Z-stack images with 1-μm step size 
were acquired at two digital zooms. Low power views at zoom 1.5X (~0.30 μm/pixel) with 
overall architectural information would allow us to clearly observe morphological features, 
while high power views at zoom 3.0X (~0.15 μm/pixel) with detailed cellular information 
would be used for precise segmentation of cells. Average power on sample was ~70 mW and 
~35 mW for the pump and Stokes beams, respectively. This power combination is higher than 
that typically used for CARS imaging. It is due to the fact that solid tumor tissues normally 
possess  a  lower  lipid  level  than  normal  tissues.  As  a  result,  a  higher  excitation  power  is 
required  to  provide  enough  image  contrast  for  observation  of  cellular  structures  in  tumor 
tissues. The acquisition time was about 4 seconds per frame with 512 x 512 pixels. Bright-
field images of their corresponding H&E slides were captured by using an Olympus BX51 
microscope and examined by a pathologist to determine the type of lesions as a standard 
control. 
2.4. Quantitative image analysis 
Cell  nucleus  segmentation:  A  semi-automated  segmentation  algorithm  was  developed  to 
accurately delineate boundaries of cell nuclei [30]. The process consists of one manual step 
and four automated steps which take approximately 5 minutes for images from each patient. 
1) Manually select a point within a cell nucleus. 2) Crop an image patch (a square window 
containing  the  interested  object)  centered  at  the  selected  point  containing  the  nucleus.  3) 
Apply a seeded watershed algorithm [31–33] to segment the image patch into background and 
foreground, and thus obtain a rough region of the cell nucleus. 4) Use intensity threshold [m-
1.75*δ, m + 1.75*δ] for identification of another rough nucleus region, where m and δ are the 
average intensity and standard deviation in a neighborhood of the center point. 5) Delineate 
the nuclear regions by overlapping the rough regions obtained from watershed and threshold 
methods (steps 3 and 4), and fit the result with an ellipse using the least square criterion [34] 
for a final boundary. An average of 27 cells for DCIS, 18 cells for IG-IDC, 16 cells for HG-
IDC, and 12 cells for ILC per image  were used for parametrical calculation.  Figure 2(B) 
provides an illustration of cell nuclear segmentation of an IDC sample shown in Fig. 2(A). 
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Fig.  2.  A  CARS  image  (A)  from  the  Z-stacks  of  an  IDC  sample,  showing  cell  nuclei 
segmentation (B), Voronoi tessellation (C), and Delaunay triangulation (D). Image size: 120 x 
120 µm
2. 
Validation of cell nuclei segmentation: One hundred cells were randomly selected from 10 
CARS images for each subtype of four breast cancer lesions: DCIS, IG-IDC, HG-IDC, and 
ILC,  to  validate  the  semi-automated  segmentation  algorithm.  The  semi-automated 
segmentation results were compared with the manual segmentation results by calculating three 
scores:  precision,  recall  and  f-score.  They  are  given  as  follows:   
'' / i i i p S S S  , 
 
' / i i i r S S S  ,      2/ f p r r p      ,  where  i S is  the  ground  truth  (manual 
segmentation  result)  of  the  i-th  cell  manually  measured,  and 
'
i S  is  the  semi-automated 
segmentation result measured by the software used in this study. Figure 3 shows the validation 
results of cell segmentation in terms of precision, recall and fscore. It can be seen that all three 
indexes are close to 90% for the 400 individual nuclei from four cancer subtypes, indicating 
the high accuracy of our cell nuclear segmentation algorithm. 
2.5. Extraction of disease-related features 
We designated seven pathological features to characterize the difference among breast cancer 
subtypes: nuclear size, lengths of major (long) and minor (short) axes of cell nucleus, Voronoi 
tessellation (Fig. 2(C)) size (approximation of cell size) [35,36], as well as average, major 
(maximum) and minor (minimum) neighbor distances of cells in the Delaunay triangulation 
graph  (Fig.  2(D))  [37,38].  Moreover,  five  parameters,  including  mean  value,  standard 
deviation, skewness, kurtosis, and entropy, were employed to evaluate the distribution of each 
feature. The mathematical definitions of skewness γ1(x), kurtosis γ2(x), and entropy H(x) are as 
follows: 
3
1( ) [( ) ] ( )
b
a x x p x dx      , 
2
42
2( ) ( ) ( ) ( ) ( ) 3
bb
aa x x p x dx x p x dx             
and  2 ( ) log ( ( )) ( )
b
a H x p x p x dx  ,  where  x  is  a  random  variable  whose  observations  are 
within [a, b], p(x) is the probability density function of x, and µ and σ denote the mean and 
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extracted to describe each CARS image. 
 
Fig. 3. Validation results of cell nuclear segmentation. DCIS: ductal carcinoma in situ, IG-IDC: 
intermediate-grade invasive ductal carcinoma, HG-IDC: High-grade invasive ductal carcinoma, 
ILC: invasive lobular carcinoma. 
2.6. Differential diagnosis analysis 
We  performed  two  analyses  to  investigate  the  separation  of  cancer  subtypes:  partial  least 
square regression (PLSR) [39–42] and semi-supervised learning (SSL) classification. PLSR is 
used  for  3-D  data  visualization,  and  SSL  is  used  to  classify  different  subtypes  of  breast 
lesions.  The  basic  idea  of  PLSR  is  to  build  a  regression  prediction  model  between  the 
observation variables X (independent variables) and the dependent variables Y [39–42]. Since 
there might be many independent variables (when the dimension of X is high), it will make the 
prediction model complicated and sensitive to the noise [39–42]. To overcome this problem, 
the PLSR approach functions to reduce a high dimension independent variable space into a 
lower  dimension  space  (dimension  reduction),  which  can  be  represented  by  only  a  few 
coordinates (latent components). Then a linear regression prediction model is built between 
the latent components (by projecting the data points from the high dimension space onto the 
latent components to obtain new coordinates of the data points in the new space) and the 
dependent variables. So, technically, the PLSR analysis is to predict dependent variables Y 
from independent variables X by extending the idea of principal component analysis (PCA) 
[39–42]. The detailed implementation of PLSR can be found in [40]. In brief, this algorithm 
employs  weight  vectors  c  and  w  to  maximize  the  correlation 
22 [cov( , )] [cov( , )] u t Yc Xw  , 
where u = Yc and t = Xw are called score vectors for Y and X, respectively. After obtaining the 
i-th score vectors ui and ti (the projection coordinates of X and Y on the i-th latent components, 
i.e. ci and wi) the process is then applied to the residual matrixes Yi and Xi to get the next set of 
score  vectors  ui+1  and  ti+1,  where  1
T
i i i i Y Y u q   ,  1
T
i i i i X X t p  ,  and  1
TT
i i i i i p X t t t   , 
1
TT
i i i i i q Y u u u   . 
After data visualization using PLSR, SSL classification analysis [43,44] was performed to 
separate cancer subtypes. The idea of SSL is to make use of both the training data and the data 
structure  information  embedded  in  the  unlabeled  data.  SSL  is  straightforwardly  used  to 
smooth  classification  results.  In  other  words,  SSL  prefers  that  the  nearby  samples  should 
belong to the same class, and the labeled samples transfer their label information outward to 
their nearby unlabeled neighbors gradually layer by layer. An intuitive example is the two 
moons shape data provided in [43,44]. Mathematically, the processes of SSL are as follows. 
Given m are data points    12 , ,..., m X x x x   which belong to c class (   1,2,..., Cc  ). The first 
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finds a non-negative matrix Fmc, which will be used to generate the labels of unlabeled data 
points, such as  argmax i j c ij yF   . The cost function of Fmc is defined as follows [43,44]: 
   
2 2
, 1 1
1
2
mm
ij i ii j jj i i
i j i
F W F D F D F Y 


     
     (1) 
where   
2 2 exp / 2 , ;
0, .
ij
ij
ij
W
ij
        
   
xx
 is an affinity matrix, D is a diagonal matrix with 
1
m
ii ij
j
DW

 ,  i F  and  j F are the i-th and j-th row vectors of F,  i Y  is the i-th row vector of 
1, ;
0, .
i
ij
i
yj
Y
yj
  
    
, and  0 ij Y  for the unlabeled data points. On the right-hand side of the above 
equation, the first term is the smoothness function which requires the neighboring data points 
to belong to the same class, while the second term is the fitting function which limits the 
labeled data points in order to be consistent with their original labels. Then the optimal  * F  
satisfies * argmax ( ) F FF  .  Differentiating    F   at * F ,  the  equation 
 
* /
FF F
      * * * 0 F SF F Y       can  be  obtained,  where
1/2 1/2 S D WD
  . 
Therefore,      * */ 1 / 1 0 F SF Y         . Letting  1/(1 ) u    and  /(1 ) u   , the 
relation   
1 * F I S Y 
   can thus be obtained [43,44]. 
To validate the classification algorithm, a leave-one (patient)-out cross-validation analysis 
was conducted. In this process, the data from one of the patients were used for testing, while 
the remaining patients’ data were used to train the classifier. Since three z-stack CARS images 
were captured for each sample, we used the voting method to manage the conflicting results 
among individual stacks. The sample’s subtype was determined according to the classification 
results of the majority of the z-stacks. For example, if two of three z-stacks were classified 
into the same class, this sample would be recognized into that class regardless of the result 
from the third stack. 
3. Results 
3.1. CARS Images of breast tissues 
Figure 4 shows a comparison of CARS images of normal breast tissue, benign proliferative 
lesion and carcinomas with their H&E stained photomicrographic images. On H&E stained 
images, normal breast tissues predominantly consist of adipose and fibrous structures (Figs. 
4(B) and 4(D)). These structures possess strong CARS signals and can be clearly recognized 
in  CARS  images,  as  shown  in  Figs.  4(A)  and  4(C),  respectively.  No  obvious  cells  were 
identified in the normal tissues with CARS, possibly because of the overwhelming CARS 
signals  from  the  fat  and  fibrous  tissue  components.  Fibroadenoma  is  a  common  benign 
biphasic fibroepithelial tumor. One of its unique features is the intracanalicular pattern, in 
which the compressed duct shows linear branching pattern with slit-like lumen, as indicated 
by the arrow in the H&E stained image shown in Fig. 4(F). The same pattern is also clearly 
identified in the CARS image, as indicated by the arrow in Fig. 4(E). 
Figure 4(H) shows the H&E stained image of a solid subtype of DCIS. The tumor cells are 
confined  within  the  basement  membrane  and  nearly  fill  the  entire  duct  space.  There  are 
prominent cytoplasmic borders with sharp outline. These features are also presented in the 
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nests, tubules, and anastomosing cell clusters, invading into the surrounding stroma, as shown 
in Fig. 4(J). All these features are distinctly observed in the CARS image shown in Fig. 4(I). 
The  CARS  and  H&E  stained  images  of  HG-IDC  are  shown  as  Figs.  4(K)  and  4(L), 
respectively,  in  which  tumor  cells  are  arranged  singly  or  in  small  clusters,  but  without 
noticeable tubule or gland formation. Figure 4(N) shows an H&E stained image of a classic 
ILC, with characteristic infiltrative pattern with single or rows of cells (Indian filing) invading 
into the stroma. This pattern is clearly presented in the CARS image, as shown in Fig. 4(M). It 
is worth noting that in some foci, the single filing infiltrative pattern of ILC is inconspicuous, 
and the tumor cells may just be dispersed in the stroma in an irregular fashion. 
 
Fig. 4. CARS images of human breast tissues taken at Raman shift of 2845 cm
1 and their H&E 
stained  images  from  similar  regions.  Images  of  (A)  adipose  and  (C)  fibrous  structures  in 
normal tissues and their H&E stained images (B) and (D). Image (E) of a kind of fibroadenoma 
(a benign lesion) and its H&E stained image (F), in which a compressed duct can be clearly 
seen as a linear branching pattern with slit-like lumen, as indicated by the arrow. Image (G) of 
DCIS and its H&E stained image (H). Images of (I) IG-IDC and (K) HG-IDC and their H&E 
stained images (J) and (L). Image (M) of ILC and its H&E stained image (N). Scale bars: 10 
μm. 
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Fig. 5. Distributions of the seven features of four subtypes of breast cancer: (A) nuclear size, 
(B) major and (C) minor radii, (D) Voronoi tessellation size, as well as (E) average, (F) major 
and (G) minor neighbor distances. 
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Fig. 6. Spatial distributions of four subtypes of breast cancer using the 35-feature set under 
PLSR analysis. 
3.2. Differential diagnosis of breast cancer 
In most cases, histological evaluation alone is sufficient to separate in situ carcinoma from 
invasive carcinomas and to separate ductal and lobular carcinoma subtypes. However, in some 
instances, the differential diagnosis of histological subtype of breast cancer may be difficult 
and cannot be reliably made with conventional H&E staining of histological sections, even by 
an experienced pathologist. Therefore, using breast tissue samples with histologically well-
characterized lesions by H&E staining, we explored whether an algorithm could reproduce 
identical  or  near-identical  morphological  characterizations  using  CARS  images.  Figure  5 
provides the distributions of the seven features for four subtypes of breast cancer. From Fig. 
5(A), 5(B) and 5(C), it can be seen that IG-IDC has larger nuclear size and longer major and 
minor  radii  with  wider  distribution  ranges  than  other  subtypes.  HG-IDC  has  narrower 
distribution range while IG-IDC has wider distribution range than other subtypes in Voronoi 
tessellation size, as shown in Fig. 5(D). IG-IDC and ILC have longer average and minor 
neighbor distances with narrower distribution ranges than other subtypes, as shown in Fig. 
5(E) and 5(G). IG-IDC has longer major neighbor distance with a wider distribution range 
than other subtypes, as shown in Fig. 5(F). Figure 6 shows the global spatial distributions of 
four subtypes of breast cancer using PLSR analysis. Here, it can be visually seen that DCIS is 
mostly separated from IG-IDC and ILC but partially overlaps with HG-IDC, and ILC is well 
separated from other subtypes while IG-IDC and HG-IDC have partial overlapping. 
The quantitative analytical results of differential diagnosis of breast cancer subtypes are 
listed in Table 1, while the classification overview is illustrated in Fig. 7. The accuracies of 
separating in situ carcinoma from invasive carcinoma are shown in Table 1(A). While 100% 
of  the  in  situ  carcinoma  is  correctly  identified  and  18%  of  the  invasive  carcinomas  are 
erroneously classified as in situ carcinoma, having an overall accuracy of 92%. This result 
could be visualized in the 3-D distribution of these cases in Fig. 6. Based on this result, a 
#148131 - $15.00 USD Received 24 May 2011; revised 24 Jun 2011; accepted 29 Jun 2011; published 5 Jul 2011
(C) 2011 OSA 1 August 2011 / Vol. 2, No. 8 / BIOMEDICAL OPTICS EXPRESS  2171classification  algorithm  was  developed  to  separate  DCIS  from  IG-IDC  and  ILC,  and  the 
results are shown in Table 1(B). By this algorithm, 96% of DCIS and 95% of IG-IDC and ILC 
samples are correctly classified with an overall accuracy of 96%. The accuracies of separating 
IDC from ILC are shown in Table 1(C). They are 100% separated from each other, which is 
also illustrated in the 3-D visualization results in Fig. 6. As shown in Table 1(D), 80% of IG-
IDC and 85% of HG-IDC were correctly separated with an overall accuracy of 83%. 
 
Fig. 7. Overview of the classification scheme. 
Table 1. Classification accuracy of separating cancer subtypes from each other (Accuracy 
= (true positive + true negative) / total testing samples) 
A. Separating in situ carcinoma from invasive carcinoma     B. Separating DCIS from IG-IDC and ILC 
   In situ  Invasive        DCIS  IG-IDC & ILC 
In situ  100%  0     DCIS  96%  4% 
Invasive  18%  82%     IG-IDC & ILC  5%  95% 
Accuracy  92%     Accuracy  96% 
C. Separating ILC from IDC     D. Separating IG-IDC from HG-IDC 
   ILC  IDC        IG-IDC  HG-IDC 
ILC  100%  0     IG-IDC  80%  20% 
IDC  0  100%     HG-IDC  15%  85% 
Accuracy  100%     Accuracy  83% 
4. Discussion 
In this exploratory study, we have demonstrated the feasibility of using CARS microscopy to 
distinguish  breast  cancer  from  normal  tissue  and  benign  proliferative  lesion,  as  well  as 
different  cancer  subtypes.  High  quality  ex  vivo  images  were  obtained  for  normal,  benign 
(fibroadenoma),  DCIS,  IDC  and  ILC  breast  tissues  by  using  a  custom-built  CARS 
microscope. Our results show that CARS microscopy is capable of characterizing breast tissue 
structures and cell types in a manner similar to H&E staining of conventional histological 
sections. On CARS images, normal breast tissues present predominantly adipose and fibrous 
structures, while fibroadenomas possess unique morphological features in accordance with 
pathological criteria. On the other hand, cancer tissues exhibit distinct cellular features with 
high cellularity. These disease-related features can be used to distinguish cancer lesions from 
normal and benign tissues. In addition, the cells of different cancer subtypes also present 
unique features, e.g., the cords and tubules for IG-IDC, the solid pattern for HG-IDC, and the 
single filing pattern for ILC. CARS microscopy was also shown to discriminate these cellular 
features  to  further  separate  cancer  subtypes.  A  computerized  platform  was  developed  to 
#148131 - $15.00 USD Received 24 May 2011; revised 24 Jun 2011; accepted 29 Jun 2011; published 5 Jul 2011
(C) 2011 OSA 1 August 2011 / Vol. 2, No. 8 / BIOMEDICAL OPTICS EXPRESS  2172perform  nuclear  segmentation  and  classification  of  different  types  and  subtypes  of  breast 
lesions.  Our  results  showed  a  good  distinction  of  cancer  from  normal  tissues  and  benign 
lesions,  as  well  as  cancer  subtypes.  Compared  to  H&E  analysis,  however,  our  approach 
presents a much faster strategy and eliminates the need for sample processing and the use of 
exogenous  contrast  agents,  thus  significantly  reducing  diagnostic  time.  The  separation  of 
some breast lesions, such as atypical ductal hyperplasia and DCIS, is more subtle and will 
likely  continue  to  require  conventional  histological  analysis.  Nonetheless,  we  have 
demonstrated that CARS imaging is reliable, sensitive and specific in discriminating between 
different subtypes of breast cancer, e.g., non-invasive in situ vs. invasive, different histological 
subtypes, e.g., DCIS vs. IG-IDC & ILC, and different histological grades of carcinoma, e.g., 
intermediate vs. high grade. Because they have direct impact on prognosis, choice of treatment 
modalities and monitoring response to therapy, such distinctions are critical. 
The detailed reasons for further separating cancer subtypes from each other are as follows. 
1) Separating in situ carcinoma from invasive carcinoma: in situ carcinomas have an excellent 
prognosis  and  are  generally  treated  with  lumpectomy  and  sometimes  radiation,  whereas 
invasive  carcinomas  have  poorer  prognosis  and  are  generally  treated  with  surgery 
(lumpectomy  or  mastectomy  with  or  without  lymph  node  removal),  chemotherapy,  and 
sometimes radiation. 2) Separating ILC from IDC: Rates of mastectomy compared to breast-
conserving surgery in ILC are slightly higher than for IDC [45], and ILC is also not a good 
candidate  for  neoadjuvant  chemotherapy  because  pathologic  complete  response-rates  are 
much lower for ILC (3%) than for IDC (15%) [46]. Two large series with long follow-up 
observation [47,48] have revealed trends showing that the prognosis of ILC in the early years 
is somewhat better than the prognosis for IDC, while this trend is reversed in later years. That 
is, after about 6 years, relapse of ILC catches up with IDC. 3) Separating IG-IDC from HG-
IDC: High-grade means that tumor cells are poorly differentiated in the Bloom-Richardson 
grading system, and poorly differentiated cancers have a worse prognosis. Patients with poor 
prognosis are usually offered more aggressive treatment, such as extensive mastectomy and 
one or more chemotherapy drugs, while patients with a good prognosis are usually offered 
less invasive treatments, such as lumpectomy and radiation or hormone therapy. 
Sometimes identifying cancer subtypes is difficult using the CARS technique because the 
histological features may be difficult to observe based on the limited field of view in the 
CARS image. As an adjunctive diagnostic approach, the quantitative analysis of cancer cells 
facilitates more accurate identification of cancer subtypes. To enable the implementation of 
this quantitative approach, cell nucleus segmentation was performed, followed by extraction 
of  seven  pathology-related  features  with  5  evaluation  indexes,  a  total  of  35  features,  to 
describe each image. The distributions of seven features for four subtypes of breast cancer are 
shown in Fig. 5, which indicates differences among subtypes. Moreover, the global spatial 
distributions of four subtypes using the 35-feature set under PLSR analysis are shown in Fig. 
6, and the results show the robustness of the algorithms in separating cancer subtypes. Finally, 
a quantitative analysis of the differential diagnosis of cancer subtypes was conducted, and the 
results show high accuracies for the separation of cancer subtypes. 
As a future study direction, 3D imaging and differential diagnosis of breast cancer using 
CARS microscopy is attractive. It can provide more information than 2D images, and allow 
tracking  of  features  from  different  levels  to  identify  3D  architecture  and  low  contrast 
structures that are difficult to appreciate from single images [49]. The 3D imaging capability 
of the CARS technique makes this aim achievable based on its nonlinear nature. Nonetheless, 
prospective studies with a larger sample size are necessary for subtypes of cancer (DCIS in 
particular) to further evaluate the efficacy of our method. Current study is still limited by the 
number of samples and might experience a larger bias. 
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We  demonstrated  that,  for  the  first  time,  the  feasibility  of  integrating  label-free  CARS 
microscopy and quantitative data analysis to classify breast cancer from normal tissue and 
benign proliferative lesion, as well as further separate cancer subtypes. This study suggests 
that quantitative CARS microscopy has the potential to be used as a routine examination tool 
to rapidly identify breast cancer ex vivo. For future studies, the label-free and fast imaging 
properties of CARS could propel this technique to become a non-invasive approach for in vivo 
and  real-time  diagnosis  of  breast  cancer  without  the  need  for  histological  staining  or 
administration  of  exogenous  contrast  agents.  Although  conventional  histological  analysis 
would remain the gold standard and would remain necessary for difficult cases requiring the 
analysis of subtle pathologic features or immunohistochemistry markers, the fact that CARS 
seems to be able to delineate major diagnostic entities shows its promise to greatly increase 
the  amount  of  information  timely  available  to  patients  and  physicians  during  biopsy  or 
excision procedures. 
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